Sepsis Diagnostics Market Size & Share 2026-2035

Sepsis Diagnostics Market Size

The sepsis diagnostics market was valued at USD 825 million in 2025. The market is projected to grow from USD 885.7 million in 2026 to USD 2.3 billion by 2035, at an 11% CAGR.

Demand is rooted in the clinical urgency of identifying infection, pathogen type, and antimicrobial-resistance markers before organ dysfunction progresses. A 2021 global analysis estimated 166 million sepsis cases and 21.4 million sepsis-related deaths, with older adults accounting for a substantial share of the disease burden ^{[1]The Lancet Global Health, Global, regional, and national sepsis incidence and mortality, 1990-2021, 2025, thelancet.com}. The World Health Organization also identifies sepsis as a frequent complication of healthcare delivery, affecting an estimated 15 per 1,000 hospitalized patients. These conditions sustain baseline demand for blood culture media and routine biomarkers while expanding the commercial case for faster molecular, host-response, and software-supported diagnostic workflows.

The market's value creation is shifting from individual tests toward connected laboratory-to-clinical pathways. Blood culture remains central to microbiological confirmation, but its turnaround limitations create room for automated culture monitoring, multiplex identification panels, MALDI-TOF systems, direct-from-blood platforms, and risk-stratification tools. Suppliers that can shorten the interval between specimen collection and treatment-relevant information are better positioned to capture both instrument placements and recurring reagent revenue.

The clinical burden makes time-to-result commercially consequential. Older patients represent a growing concentration of sepsis cases, while hospitals are being pressed to standardize recognition, measurement, and treatment processes ^{[2]Centers for Disease Control and Prevention, Hospital Sepsis Program Core Elements, August 2023, cdc.gov}. This combination favors platforms that fit established laboratory infrastructure but provide earlier organism, resistance, or host-response information. The constraint is that premium technologies must demonstrate workflow and treatment value sufficient to overcome capital costs, reimbursement variability, and regulatory requirements.

Key Drivers

Infectious-disease burden and antimicrobial resistance

Sepsis volume creates recurring demand across the diagnostic chain because patients frequently require initial cultures, pathogen identification, susceptibility testing, and biomarker monitoring. In the United States, at least 1.7 million adults develop sepsis annually, and at least 350,000 die during hospitalization or are discharged to hospice. The size of this care burden supports broad use of culture-based testing while increasing the value assigned to earlier diagnostic certainty.

Antimicrobial resistance raises the commercial importance of tests that distinguish pathogens and resistance determinants quickly. The WHO estimated that bacterial antimicrobial resistance was associated with 4.95 million deaths in 2019, including 1.27 million deaths directly attributable to resistance. In bloodstream infections, this makes a delayed or incomplete microbiological result more than a laboratory issue: it can delay appropriate therapy and increase demand for multiplex molecular panels and rapid susceptibility-testing capabilities.

Government programs and institutional accountability

Sepsis has increasingly been embedded in hospital quality and safety infrastructure. U.S. sepsis performance measures require blood-culture collection before antibiotic administration in relevant care episodes, preserving the role of blood culture media and automated detection systems in routine procurement. The CDC's Hospital Sepsis Program Core Elements further encourages leadership commitment, multidisciplinary teams, standardized procedures, data systems, and outcome tracking.

Government involvement also affects the market through program funding and development partnerships. In fiscal year 2024, Congress appropriated USD 3 million to the CDC for sepsis-related work, including quality measures, surveillance integration, and performance benchmarks. Separately, Siemens Healthineers received a USD 5.5 million NIAID contract to develop an NGS-based approach for bacterial and fungal sepsis pathogens and antimicrobial-resistance profiling. Such programs reduce some early development risk for advanced platforms while making measurable diagnostic performance more important to hospital buyers.

Technology transition toward actionable results

Automation reduces manual handling and supports continuous culture monitoring. BD's BACTEC FX system provides continuous monitoring and reports positive blood cultures as they are detected, allowing laboratories to trigger downstream identification workflows sooner. At the post-culture stage, Bruker's MBT Sepsityper IVD workflow identifies microorganisms directly from positive blood cultures in approximately 15-20 minutes, avoiding a conventional subculture step.

Molecular technologies are expanding the amount of clinically actionable information available after culture positivity. A published assessment of the BioFire BCID2 panel reported high sensitivity for key bloodstream pathogens and resistance markers, supporting faster organism-directed treatment decisions. Direct-from-blood testing addresses an earlier bottleneck. T2 Biosystems' expanded T2Bacteria Panel detects designated bacterial pathogens directly from whole blood, without waiting for a positive blood culture. The strategic significance is not simply shorter turnaround; it is the potential to alter ordering patterns, escalation decisions, and reagent mix within acute-care laboratories.

Software is becoming more relevant as hospitals seek to connect laboratory output with triage and stewardship processes. In April 2024, the FDA authorized the Sepsis ImmunoScore through the de novo pathway, creating an FDA-authorized AI-enabled sepsis diagnostic category. The category remains early, but it strengthens the business case for laboratory information, EHR integration, and clinical-decision support as purchasing criteria rather than ancillary capabilities.

Awareness and protocol adoption

Awareness initiatives convert clinical concern into repeatable ordering behavior. The CDC's Get Ahead of Sepsis materials support recognition of sepsis, infection prevention, and communication with patients and care teams. More standardized recognition increases the likelihood that sepsis workups occur early enough to require blood cultures, lactate testing, biomarker assessment, and follow-on microbiology.

The effect is most meaningful where education is paired with hospital protocols and laboratory capacity. Awareness without diagnostic access expands the identification gap; awareness coupled with automated culture systems, immunoassays, or centralized molecular testing increases addressable test volume. This distinction is especially important in emerging healthcare markets, where demand growth may initially favor scalable consumables before capital-intensive platforms achieve broad penetration.

Key Restraints

Capital intensity and test economics

Advanced sepsis testing can impose costs at several points: instrument acquisition, service contracts, single-use molecular cartridges, validation, connectivity, and skilled laboratory staffing. These costs are most restrictive where public procurement emphasizes unit price, laboratories have low daily testing volumes, or reimbursement does not recognize the avoided cost of delayed antimicrobial optimization. The resulting adoption pattern is uneven: conventional cultures, basic immunoassays, and high-throughput analyzers remain accessible across a wider provider base than direct-from-blood molecular systems or specialized mass-spectrometry platforms.

The restraint is particularly consequential for smaller hospitals. A centralized reference laboratory may justify high-throughput molecular capability through pooled volume, while a community facility may lack enough sepsis testing to support the same fixed-cost structure. Suppliers must therefore balance premium platform positioning with placement models, reagent-rental arrangements, and workflows that can integrate with pre-existing analyzers.

Regulatory complexity

Novel diagnostic categories face longer paths to commercialization because clinical claims, analytical performance, intended-use populations, and software functions must be substantiated. The FDA distinguishes among 510(k), de novo, and premarket approval pathways depending on device risk and predicate availability. For diagnostics combining algorithms, host-response markers, or direct-from-blood detection, the evidence burden can be substantial because the product is expected to influence high-acuity treatment decisions.

Europe's transition to the In Vitro Diagnostic Medical Device Regulation has similarly increased requirements for clinical evidence and notified-body involvement for many IVD products. These requirements can delay launches, particularly for smaller companies, but they also raise barriers to entry. Established vendors with regulatory infrastructure and clinical-evidence capabilities may therefore benefit as emerging platforms move from research use to routine clinical adoption.

Our primary research with U.S. acute care hospitals indicates that 73% had sepsis teams in 2023, while only 55% had integrated antibiotic stewardship into sepsis care. This implementation gap aligns with the USD 681.4 million automated diagnostics segment in 2025, which accounted for 82.6% of market revenue. The implication is that demand for automation is established, but suppliers that integrate diagnostic output with stewardship workflows have a clearer route to incremental adoption than suppliers offering isolated test performance alone.

Sepsis Diagnostics Market Segment Analysis

By Product

Blood culture media generated USD 282.1 million in 2025, accounting for 34.2% of market revenue. Its scale reflects the product's non-discretionary role in sepsis workups: even when hospitals adopt advanced identification technologies, blood culture collection remains a central entry point for many patients. Supply reliability is therefore commercially important. A 2024 disruption in BD BACTEC blood culture media availability prompted a CDC Health Alert Network communication, illustrating the operational consequences of concentrated supply for a foundational consumable ^{[3]Centers for Disease Control and Prevention, HAN 00512: Disruptions in Supply of BD BACTEC Blood Culture Media, July 2024, cdc.gov}.

Assay kits and reagents represented USD 244.3 million, or 29.6%, of 2025 revenue. This segment benefits from recurring utilization tied to installed platforms. Procalcitonin assays, multiplex panels, and other biomarker reagents create repeat revenue that grows with testing intensity rather than only with new instrument placements. Roche, Siemens Healthineers, Abbott, and Thermo Fisher participate in procalcitonin-based testing across immunoassay portfolios ^{[4]Roche Diagnostics, Elecsys BRAHMS Procalcitonin, diagnostics.roche.com}.

Instruments generated USD 195.1 million in 2025, representing 23.6% of revenue. The segment is shaped by replacement cycles, laboratory consolidation, and multi-year agreements that combine capital equipment with consumable commitments. Automated culture systems and MALDI-TOF analyzers can create switching costs because laboratories validate workflows, train staff, and connect instruments to laboratory information systems.

Software accounted for USD 104.1 million in 2025, or 12.6% of revenue. Its relative importance is increasing because buyers increasingly evaluate diagnostic platforms on interoperability, result routing, and the ability to support clinical-quality programs. Software revenue is therefore tied to the movement from standalone instruments toward connected sepsis-management pathways.

By Technology

Microbiology was the leading technology segment, generating USD 316.8 million in 2025 and accounting for 38.4% of the market. Blood culture remains the reference workflow for organism recovery and downstream susceptibility assessment, making microbiology indispensable despite slower initial turnaround. MALDI-TOF has improved the value proposition of culture-based pathways by sharply reducing the time from culture positivity to species-level identification.

Molecular diagnostics generated USD 201.5 million in 2025, representing 24.4% of market revenue. Its commercial advantage lies in multiplexing pathogens and resistance markers within clinically relevant timeframes. The segment is also positioned to gain from direct-from-blood applications, although broad adoption will depend on clinical evidence, pricing, laboratory throughput, and reimbursement.

Immunoassays contributed USD 232.3 million, or 28.1%, of 2025 revenue. Procalcitonin remains a major commercial anchor because it can be run on installed core-laboratory analyzers and used within sepsis-risk and antibiotic-stewardship workflows. Roche's Elecsys IL-6 immunoassay received CE marking in October 2023 for neonatal sepsis use in countries accepting the CE Mark, adding a differentiated neonatal application to biomarker testing.

Flow cytometry represented USD 75.2 million, or 9.1%, of 2025 revenue. The technology supports host-response assessment, including monocyte distribution width measurements that can be produced through compatible hematology analyzers. Its adoption potential is strongest where emergency departments and laboratories can use existing analyzer infrastructure rather than purchase dedicated equipment.

By Method

Automated diagnostics dominated the market with USD 681.4 million in 2025, equal to 82.6% of total revenue. Continuous culture monitoring, automated immunoassay systems, and integrated identification platforms reduce manual intervention and improve consistency in high-volume hospital laboratories. The segment's lead reflects workflow economics as much as analytical performance: scarce laboratory labor and 24-hour clinical demand make manual processes difficult to sustain at scale.

Conventional diagnostics generated USD 143.6 million in 2025, accounting for 17.4% of market revenue. Conventional workflows remain relevant in lower-volume laboratories and cost-constrained facilities, but their role is increasingly concentrated in settings where capital budgets, technical staffing, or test volumes do not support automation.

By Pathogen Type

Bacterial sepsis was the largest pathogen segment, generating USD 363.8 million in 2025 and representing 44.1% of revenue. Demand is reinforced by the need to determine both organism identity and resistance profile, particularly for bloodstream infections involving resistant Gram-negative and Gram-positive pathogens. T2Bacteria and BioFire BCID2 illustrate the growing commercial focus on tests that pair bacterial detection with faster therapeutic direction.

Fungal sepsis generated USD 188.0 million in 2025, representing 22.8% of revenue. The segment's growth opportunity is linked to diagnostic difficulty in critically ill and immunocompromised populations. T2Candida enables direct-from-blood detection of targeted Candida species and received FDA clearance for pediatric use in September 2024. The pediatric expansion broadens the addressable population while highlighting the need for evidence tailored to high-risk clinical subgroups.

Other pathogen types accounted for USD 273.1 million in 2025, or 33.1% of revenue. This category includes polymicrobial, viral, parasitic, and difficult-to-characterize infectious causes. Its relevance reflects the limits of narrow target panels and the growing interest in broader molecular and sequencing-based approaches, although these technologies remain subject to clinical-validation and economic constraints.

By End Use

Hospitals were the largest end-use segment, generating USD 325.0 million in 2025 and accounting for 39.4% of revenue. They purchase across the entire workflow, from culture bottles and analyzers to molecular panels and clinical-decision support. Their importance is reinforced by quality measures, ICU volume, and the need to support emergency, inpatient, and critical-care services around the clock.

Diagnostic centers generated USD 236.8 million in 2025, equal to 28.7% of revenue. Centralized laboratories can improve the economics of advanced testing by concentrating specimen volume and technical expertise. This model is particularly relevant for smaller hospitals and clinics that need access to rapid pathogen identification but cannot justify dedicated high-complexity equipment.

Clinics generated USD 147.7 million in 2025, or 17.9% of revenue. Their use case is weighted toward triage, lactate measurement, and referral decisions rather than complete microbiological workups. Abbott's i-STAT point-of-care portfolio supports bedside blood-gas and lactate testing in acute-care workflows.

Other end users generated USD 115.5 million in 2025, representing 14.0% of revenue. This group includes research institutions, long-term care settings, and specialized medical programs. Demand is generally more fragmented, but these users can contribute to clinical validation, decentralized-testing adoption, and emerging applications for molecular platforms.

The strongest competitive opportunity is at the point where conventional workflows leave an information gap. Fungal diagnostics illustrate this tension: culture-based pathways remain widely used, but direct-from-blood testing can address delays in selected high-risk patients. Suppliers that pair specialized rapid tests with evidence-based testing algorithms will be better positioned than those relying solely on broad claims of faster turnaround.

Sepsis Diagnostics Market Regional Analysis

North America

North America generated USD 302.8 million in 2025 and represented 36.7% of global market revenue. The United States accounted for USD 283.7 million, while Canada contributed USD 19.1 million. High acute-care capacity, established laboratory infrastructure, reimbursement resources, and regulatory activity support the region's demand for advanced diagnostics.

U.S. hospital demand is reinforced by the scale of sepsis admissions and institutional programs that formalize early identification and treatment ^{[5]Centers for Disease Control and Prevention, Sepsis: Data and Reports, July 2024, cdc.gov}. FDA authorizations for new diagnostic categories also increase visibility among laboratories, clinicians, and hospital procurement teams. The region therefore remains a primary launch market for direct-from-blood, host-response, and AI-enabled platforms, although adoption continues to depend on evidence of clinical and economic utility.

Europe

Europe generated USD 222.3 million in 2025. Germany, the UK, France, Spain, Italy, and the Netherlands are core markets because of established hospital systems, laboratory automation, and antimicrobial-stewardship programs.

Germany's critical-care burden supports sustained demand for rapid microbiology. The INSEP study reported a severe sepsis and septic shock point prevalence of 17.9% across participating ICUs and an incidence of 11.64 cases per 1,000 ICU days ^{[6]PubMed, The Prevalence and Incidence of Severe Sepsis and Septic Shock in German Intensive Care Units: The INSEP Study, 2016, pubmed.ncbi.nlm.nih.gov}. At the same time, the IVDR transition raises evidence and compliance requirements for diagnostic manufacturers. This may slow entry for novel tests, but it also favors companies that can sustain clinical-performance studies and regulatory support across multiple national markets.

Asia Pacific

Asia Pacific is the fastest-growing regional market, with an estimated CAGR of approximately 11.5% through 2035. China and India are central to incremental instrument placements as critical-care capacity and laboratory modernization expand. Japan, South Korea, and Australia provide mature markets for advanced microbiology, immunoassay, and molecular platforms.

The region's commercial trajectory will vary by country. Large urban hospitals can support automated culture and molecular platforms, while lower-tier facilities may prioritize culture media, core-laboratory immunoassays, and centralized referral testing. Suppliers that align placement models with local laboratory capacity are likely to capture growth more effectively than those applying a uniform premium-platform strategy.

Latin America

Brazil, Mexico, and Argentina form the principal markets in Latin America. Demand is concentrated in urban tertiary hospitals and private laboratory networks, while public-sector facilities often face budget restrictions that limit adoption of capital-intensive technologies. This favors market entry through blood culture consumables, routine biomarkers, and scalable automated workflows.

The region's burden of sepsis supports long-term unmet need, but purchasing decisions remain highly sensitive to test cost, reimbursement, and distributor coverage. Commercial success will depend on demonstrating that rapid testing can be implemented within constrained public-health budgets rather than only within specialized private hospitals.

Middle East and Africa

Middle East and Africa contains sharply different demand environments. Saudi Arabia and the UAE offer capital-investment opportunities through hospital expansion and advanced-care infrastructure, whereas many African health systems face limitations in laboratory capacity, supply-chain reliability, and affordability.

The World Health Organization identifies sepsis as a major global health concern with especially serious consequences where timely diagnosis and treatment are less accessible. In this region, growth is likely to begin with dependable culture media, basic biomarker testing, portable systems, and laboratory-capacity upgrades. Higher-complexity molecular platforms will remain concentrated in referral centers until procurement models and technical support networks broaden.

Asia Pacific presents the strongest growth runway because new ICU and laboratory capacity creates opportunities to establish instrument-and-reagent relationships before workflows become entrenched. In Latin America and Middle East and Africa, the near-term commercial opportunity is more selective: suppliers need cost-effective consumables, resilient distribution, and service models that overcome procurement constraints before expecting broad uptake of premium rapid platforms.

Sepsis Diagnostics Market Share & Competitive Landscape

The market is moderately consolidated, with the five largest participants collectively accounting for approximately 60% of global revenue in 2025. Competitive advantage is built on installed instrument bases, reagent portfolios, regulatory capabilities, clinical evidence, service networks, and laboratory-information connectivity.

F. Hoffmann-La Roche Ltd.

Roche participates primarily through its Elecsys BRAHMS Procalcitonin assay portfolio, which supports sepsis risk assessment and antibiotic-management workflows on cobas e analyzers. Its CE-marked Elecsys IL-6 assay for neonatal sepsis creates a differentiated position in a clinically specialized population ^{[7]Roche, Roche IL-6 Immunoassay First IL-6 Approved for Neonatal Sepsis, October 2023, roche.com}.

Thermo Fisher Scientific Inc.

Thermo Fisher's B·R·A·H·M·S PCT franchise supports biomarker testing for sepsis and inflammation, while its broader clinical laboratory portfolio provides distribution and customer access across hospital laboratories ^{[8]Thermo Fisher Scientific, Sepsis Diagnostics: B·R·A·H·M·S PCT, thermofisher.com}. The company's positioning is strongest where procalcitonin is embedded in stewardship and critical-care workflows.

Abbott Laboratories

Abbott combines core-laboratory procalcitonin testing through the Alinity platform with point-of-care capabilities through i-STAT. This provides exposure to both emergency-department triage and subsequent laboratory-based monitoring.

Beckman Coulter Inc. (Danaher Corporation)

Beckman Coulter offers procalcitonin testing and the Early Sepsis Indicator, which uses monocyte distribution width as a host-response marker. Its installed hematology-analyzer base can support adoption where laboratories seek early risk information without adding a dedicated sepsis instrument.

Siemens Healthineers

Siemens Healthineers markets the Atellica IM B·R·A·H·M·S PCT assay for sepsis-related clinical use. Its NIAID-supported work on an NGS-based bacterial and fungal sepsis test indicates a strategic effort to participate in culture-independent pathogen detection.

Becton, Dickinson and Company

BD has a leading presence in blood culture media and automated culture detection through the BACTEC franchise. Its partnership with Bruker broadens the workflow proposition by linking blood-culture infrastructure with MALDI-TOF identification capabilities. The 2024 media shortage also demonstrated the operational importance of the company's supply chain to U.S. laboratory continuity.

bioMérieux SA

bioMerieux offers an integrated portfolio including BACT/ALERT blood culture systems, VITEK identification and susceptibility platforms, BioFire multiplex panels, and laboratory middleware. The breadth of this portfolio supports bundled laboratory relationships and helps the company compete across culture, molecular, and workflow-management categories.

Bio-Rad Laboratories Inc.

Bio-Rad participates through droplet digital PCR systems used in research and translational-diagnostics settings. Its role is more closely tied to assay development and advanced molecular research than to broad routine sepsis testing, but it can benefit as clinical applications for digital PCR mature.

Bruker Corporation

Bruker's MALDI Biotyper systems support rapid organism identification from positive cultures. Its differentiation rests on reducing the time between culture positivity and species-level identification, an important step in accelerating downstream treatment decisions.

T2 Biosystems Inc.

T2 Biosystems is differentiated by direct-from-blood detection using T2 Magnetic Resonance technology. The T2Bacteria Panel and T2Candida Panel address bacterial and fungal pathogens without waiting for culture positivity. Commercial expansion depends on demonstrating where this speed delivers sufficient clinical and economic value to justify targeted adoption.

Recent Industry Developments

February 2024 - T2 Biosystems expanded the T2Bacteria Panel

T2 Biosystems received FDA 510(k) clearance to add *Acinetobacter baumannii* to the T2Bacteria Panel, expanding direct-from-blood detection coverage for selected bacterial bloodstream infections.

April 2024 - FDA authorized Sepsis ImmunoScore

The FDA authorized Sepsis ImmunoScore through the de novo pathway, establishing an FDA-authorized AI-enabled diagnostic tool for sepsis.

September 2024 - Pediatric clearance for T2Candida

T2 Biosystems received FDA clearance for pediatric use of the T2Candida Panel, extending direct-from-blood fungal testing to children.

Fiscal year 2024 - U.S. funding for CDC sepsis work

Congress appropriated USD 3 million to the CDC for sepsis-related quality-measure development, surveillance integration, and hospital performance benchmarking.

October 2023 - Roche received CE marking for Elecsys IL-6

Roche announced CE marking for the Elecsys IL-6 immunoassay for neonatal sepsis diagnosis in countries accepting the CE Mark.

August 2023 - CDC launched Hospital Sepsis Program Core Elements

The CDC released a framework for hospitals to strengthen sepsis programs through leadership, standardized practices, stewardship integration, and outcome measurement.

July 2024 - CDC issued an alert on BD BACTEC media supply disruption

The CDC issued a Health Alert Network notice regarding disruptions in the supply of BD BACTEC blood culture media.